Anti-tumor Response
Anti-tumor Response - Related Videos
04:13
A Technique to Assess the In Vivo Localization of Tumor-Specific Antibodies
0 Views •
2025
This video demonstrates a technique to study the in vivo localization of tumor-specific antibodies in a mouse tumor xenograft model. Upon subcutaneously injecting cancer cells into mice for tumor formation, fluorescently-labeled antibodies are injected that bind to tumor-specific receptors, enabling in vivo assessment of antibody localization via imaging.
05:22
A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses
0 Views •
2025
Multiplex fluorescence immunoassays are becoming a reference for serology testing. Their application, however, is limited by the complexity and time-consuming bead-analyte coupling processes. This report presents a semi-automated, reproducible multiplex microsphere bead coupling protocol that is comparable to the standard method while considerably reducing time to results.
03:10
In Vivo Fluorescence Imaging to Localize Antibodies in a Mouse Tumor Xenograft Model
0 Views •
2025
The video demonstrates a fluorescence imaging method for in vivo antibody localization in a mouse tumor xenograft model. It involves the injection of tumor cells in a mouse to generate solid xenografts beneath the skin. Subsequent injection of fluorescent antibodies confirms specific localization through enhanced fluorescence signals within the tumor xenograft.
02:39
An In Vivo PET Imaging Technique to Detect Tumors in a Murine Model Using Radiolabeled Antibodies
0 Views •
2025
This video demonstrates a technique involving a radioimmunoconjugate for the in vivo imaging of a tumor in a mouse model. Upon injection of the radioimmunoconjugate, the antibodies of the conjugate bind to a specific membrane antigen on the cancer cells. The radiotracer of the conjugate emits positrons that interact with neighboring electrons to produce energy, which is detected by a positron emission tomography (PET) scanner to create an image of the tumor.
02:44
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
0 Views •
2025
This video demonstrates a method for tracking bispecific antibody-induced T cell trafficking to tumors in a mouse model. Luciferase-transduced effector T cells are injected into a mouse with a subcutaneous tumor cell xenograft. Bispecific antibodies are then introduced, binding to T cells and the tumor cells. The localization of the T cells is tracked using bioluminescent imaging, with the magnitude of the signal indicating the extent of T cell infiltration into the tumor.
FAQs
When tumor-associated antigens are presented by antigen-presenting cells, cytotoxic T lymphocytes receive the antigen-specific activation needed to target malignant cells. This creates a route for adaptive immune recognition rather than relying only on general cellular stress signals. In experimental or clinical contexts, this axis helps explain how tumor antigen visibility can influence immune elimination and disease control.
Natural killer cells detect cellular stress and can kill susceptible targets without prior antigen-specific priming. This gives the anti-tumor response an innate immune component that operates differently from cytotoxic T-lymphocyte recognition of presented tumor-associated antigens. Considering both pathways helps researchers evaluate how malignant cells may remain vulnerable even when antigen-specific adaptive recognition is limited.
Cytokines and immune checkpoints regulate the activity of immune cells involved in tumor control. Their influence helps determine whether recognition and killing remain coordinated or become restrained. This regulatory balance matters because an effective response requires immune activity against malignant cells while remaining subject to signaling controls that can shape the strength and outcome of the reaction.
Tumors can weaken immune control by suppressing immune signaling or evading recognition. Either change can reduce the effectiveness of cytotoxic lymphocytes, natural killer cells, or their coordination, allowing malignant cells to persist. These escape mechanisms are important when interpreting tumor progression because the presence of immune cells alone does not establish that elimination will occur.
Checkpoint blockade is relevant because immune checkpoints are regulatory elements that shape the strength of anti-tumor reactions. Blocking these pathways is an immunotherapeutic strategy intended to counter inhibitory regulation and support immune activity against malignant cells. Its scientific importance lies in connecting the molecular regulation of immunity with therapeutic efforts to limit tumor development or progression.
Cellular therapies apply knowledge of immune-cell activity to cancer treatment strategies. Their relevance follows from the roles of cytotoxic T lymphocytes and natural killer cells in recognizing or killing malignant targets. Studying these therapies can therefore connect mechanistic immunology with interventions designed to strengthen immune elimination, while also clarifying why responses may differ among tumors.
Biomarkers help link features of the anti-tumor response with the likelihood of responding to immunotherapy. Their identification can support prediction of treatment response and provide a way to compare immune activity with clinical outcomes. In research, this makes biomarkers valuable for evaluating checkpoint blockade, cellular therapies, and the immune conditions associated with tumor control.